NO314685B1 - Anvendelse av cGMP-fosfodiesteraseinhibitorer for fremstilling av et medikament for behandling av erektil dysfunksjon eller seksuelldysfunksjon forbundetmed klitorisforstyrrelser hos en kvinne - Google Patents

Anvendelse av cGMP-fosfodiesteraseinhibitorer for fremstilling av et medikament for behandling av erektil dysfunksjon eller seksuelldysfunksjon forbundetmed klitorisforstyrrelser hos en kvinne Download PDF

Info

Publication number: NO314685B1
Authority: NO; Norway
Prior art keywords: 3alkyl; alkyl; optionally; hydrogen; compound
Prior art date: 1995-07-14

Application number

NO19980153A

Other languages

English (en)

Norwegian (no)

Other versions

NO980153L (no

NO980153D0 (no

Inventor

Alain Claude-Marie Daugan

Original Assignee

Icos Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-14

Filing date

1998-01-13

Publication date

2003-05-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10777695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO314685(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-01-13 Application filed by Icos Corp filed Critical Icos Corp

1998-01-13 Publication of NO980153D0 publication Critical patent/NO980153D0/no

1998-03-10 Publication of NO980153L publication Critical patent/NO980153L/no

2003-05-05 Publication of NO314685B1 publication Critical patent/NO314685B1/no

Links

238000011282 treatment Methods 0.000 title claims description 17
239000003814 drug Substances 0.000 title claims description 13
201000001881 impotence Diseases 0.000 title claims description 13
208000010228 Erectile Dysfunction Diseases 0.000 title claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 8
238000004519 manufacturing process Methods 0.000 title claims description 8
201000001880 Sexual dysfunction Diseases 0.000 title claims description 4
231100000872 sexual dysfunction Toxicity 0.000 title claims description 4
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title description 8
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title description 2
239000002571 phosphodiesterase inhibitor Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 66
150000003839 salts Chemical class 0.000 claims description 17
125000000217 alkyl group Chemical group 0.000 claims description 14
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
229940079593 drug Drugs 0.000 claims description 11
FFCZQVKVWGGQFB-UHFFFAOYSA-N 9h-pyrido[3,4-b]indole-1,4-dione Chemical compound N1C2=CC=CC=C2C2=C1C(=O)N=CC2=O FFCZQVKVWGGQFB-UHFFFAOYSA-N 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 9
150000002367 halogens Chemical class 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 6
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
150000002431 hydrogen Chemical class 0.000 claims description 6
230000003449 preventive effect Effects 0.000 claims description 6
239000012453 solvate Substances 0.000 claims description 6
241001465754 Metazoa Species 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
125000002619 bicyclic group Chemical group 0.000 claims description 3
230000004064 dysfunction Effects 0.000 claims description 3
125000005842 heteroatom Chemical group 0.000 claims description 3
229910052757 nitrogen Chemical group 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
239000011593 sulfur Chemical group 0.000 claims description 3
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 3
229930192474 thiophene Chemical group 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
150000003973 alkyl amines Chemical class 0.000 claims description 2
125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
239000000203 mixture Substances 0.000 description 23
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
239000000243 solution Substances 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
239000002904 solvent Substances 0.000 description 12
238000000034 method Methods 0.000 description 10
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000004480 active ingredient Substances 0.000 description 9
239000000543 intermediate Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
238000003818 flash chromatography Methods 0.000 description 7
239000003826 tablet Substances 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 6
239000011734 sodium Substances 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000002585 base Substances 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
230000008020 evaporation Effects 0.000 description 5
230000008018 melting Effects 0.000 description 5
238000002844 melting Methods 0.000 description 5
238000010992 reflux Methods 0.000 description 5
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000001035 drying Methods 0.000 description 4
239000008187 granular material Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
-1 eitrate Chemical compound 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000018052 penile erection Effects 0.000 description 3
210000003899 penis Anatomy 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
229940126062 Compound A Drugs 0.000 description 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
229940124639 Selective inhibitor Drugs 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
210000003029 clitoris Anatomy 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
210000005226 corpus cavernosum Anatomy 0.000 description 2
239000012043 crude product Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
150000008282 halocarbons Chemical class 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
GAWAYYRQGQZKCR-UWTATZPHSA-N (2r)-2-chloropropanoic acid Chemical compound C[C@@H](Cl)C(O)=O GAWAYYRQGQZKCR-UWTATZPHSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
102000004008 5'-Nucleotidase Human genes 0.000 description 1
ARLVFKCLBYUINL-UHFFFAOYSA-N 9h-pyrido[3,4-b]indole-3-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1C=NC(C(=O)O)=C2 ARLVFKCLBYUINL-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010057671 Female sexual dysfunction Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010078321 Guanylate Cyclase Proteins 0.000 description 1
102000014469 Guanylate cyclase Human genes 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010057672 Male sexual dysfunction Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229940127315 Potassium Channel Openers Drugs 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
PXRIAVXPRVICRE-UHFFFAOYSA-N benzenesulfonic acid;4-methylbenzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1.CC1=CC=C(S(O)(=O)=O)C=C1 PXRIAVXPRVICRE-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
229960001701 chloroform Drugs 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000006345 epimerization reaction Methods 0.000 description 1
230000001856 erectile effect Effects 0.000 description 1
210000005225 erectile tissue Anatomy 0.000 description 1
239000000469 ethanolic extract Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000001752 female genitalia Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical class OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007915 intraurethral administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
210000000260 male genitalia Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
KCUNTYMNJVXYKZ-SNVBAGLBSA-N methyl (2r)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-SNVBAGLBSA-N 0.000 description 1
JUKHNCNDFOAFLT-UHFFFAOYSA-N methyl 1-(1,3-benzodioxol-5-yl)-2-(2-chloroacetyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylate Chemical compound C1=C2OCOC2=CC(C2C3=C(C4=CC=CC=C4N3)CC(N2C(=O)CCl)C(=O)OC)=C1 JUKHNCNDFOAFLT-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
FVSUYFWWFUVGRG-UHFFFAOYSA-N naphthalen-1-ylurea Chemical compound C1=CC=C2C(NC(=O)N)=CC=CC2=C1 FVSUYFWWFUVGRG-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960003418 phenoxybenzamine Drugs 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
229940081310 piperonal Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
201000011264 priapism Diseases 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
239000000047 product Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108010043671 prostatic acid phosphatase Proteins 0.000 description 1
239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Networks Using Active Elements (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Credit Cards Or The Like (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO19980153A 1995-07-14 1998-01-13 Anvendelse av cGMP-fosfodiesteraseinhibitorer for fremstilling av et medikament for behandling av erektil dysfunksjon eller seksuelldysfunksjon forbundetmed klitorisforstyrrelser hos en kvinne NO314685B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9514464.8A GB9514464D0 (en)	1995-07-14	1995-07-14	Medicaments
PCT/EP1996/003024 WO1997003675A1 (en)	1995-07-14	1996-07-11	Use of cgmp-phosphodiesterase inhibitors to treat impotence

Publications (3)

Publication Number	Publication Date
NO980153D0 NO980153D0 (no)	1998-01-13
NO980153L NO980153L (no)	1998-03-10
NO314685B1 true NO314685B1 (no)	2003-05-05

Family

ID=10777695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19980153A NO314685B1 (no)	1995-07-14	1998-01-13	Anvendelse av cGMP-fosfodiesteraseinhibitorer for fremstilling av et medikament for behandling av erektil dysfunksjon eller seksuelldysfunksjon forbundetmed klitorisforstyrrelser hos en kvinne

Country Status (24)

Country	Link
US (2)	US6140329A (cs)
EP (1)	EP0839040B1 (cs)
JP (1)	JP4169365B2 (cs)
CN (2)	CN1311828C (cs)
AT (1)	ATE327756T1 (cs)
AU (1)	AU704955B2 (cs)
BR (1)	BR9609758A (cs)
CA (1)	CA2226784C (cs)
CY (2)	CY2563B1 (cs)
CZ (1)	CZ289686B6 (cs)
DE (1)	DE69636193T2 (cs)
DK (1)	DK0839040T3 (cs)
ES (1)	ES2267111T3 (cs)
GB (1)	GB9514464D0 (cs)
HU (1)	HU228369B1 (cs)
IL (1)	IL122870A (cs)
MX (2)	MXPA02009987A (cs)
NO (1)	NO314685B1 (cs)
PL (2)	PL185737B1 (cs)
PT (1)	PT839040E (cs)
RU (1)	RU2181288C2 (cs)
SI (1)	SI0839040T1 (cs)
SK (2)	SK284141B6 (cs)
WO (1)	WO1997003675A1 (cs)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6143746A (en) *	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US5958926A (en) *	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en)	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
CA2395558C (en)	1997-11-12	2007-07-17	Bayer Aktiengesellschaft	Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
WO1999043674A1 (en) *	1998-02-27	1999-09-02	Kyowa Hakko Kogyo Co., Ltd.	Remedies for erectile dysfunction
AU4068599A (en) *	1998-05-20	1999-12-06	Schering Corporation	Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
EP0967284A1 (en) *	1998-05-28	1999-12-29	Pfizer Limited	Phosphodiesterases
US6974838B2 (en)	1998-08-24	2005-12-13	Sepracor Inc.	Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en)	1999-08-11	2002-01-15	Sepracor, Inc.	Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en)	1998-08-24	2001-12-18	Sepracor, Inc.	Methods of treating and preventing attention deficit disorders
US6476078B2 (en)	1999-08-11	2002-11-05	Sepracor, Inc.	Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6326379B1 (en)	1998-09-16	2001-12-04	Bristol-Myers Squibb Co.	Fused pyridine inhibitors of cGMP phosphodiesterase
JP2000178204A (ja) *	1998-10-05	2000-06-27	Eisai Co Ltd	ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
WO2000020033A1 (en) *	1998-10-05	2000-04-13	Eisai Co., Ltd.	Tablets immediately disintegrating in the oral cavity
JP2000191518A (ja) *	1998-10-19	2000-07-11	Eisai Co Ltd	溶解性の改善された口腔内速崩壊性錠剤
UA67802C2 (uk)	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
AU3724400A (en) *	1999-03-08	2000-09-28	Merck & Co., Inc.	Methods and compositions for treating erectile dysfunction
US6451807B1 (en) *	1999-04-30	2002-09-17	Lilly Icos, Llc.	Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6943166B1 (en) *	1999-04-30	2005-09-13	Lilly Icos Llc.	Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6613768B1 (en) *	1999-04-30	2003-09-02	Lilly Icos Llc	Treatment of female arousal disorder
ES2187234A1 (es) *	1999-04-30	2003-05-16	Lilly Icos Llc	Forma de dosificacion oral para tratar la disfuncion sexual.
PT1200090E (pt) *	1999-08-03	2013-11-25	Icos Corp	Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual.
US6399826B1 (en)	1999-08-11	2002-06-04	Sepracor Inc.	Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9922124D0 (en) *	1999-09-17	1999-11-17	Pfizer Ltd	Phosphodiesterase enzymes
US6436944B1 (en) *	1999-09-30	2002-08-20	Pfizer Inc.	Combination effective for the treatment of impotence
HK1049834A1 (zh)	1999-10-11	2003-05-30	辉瑞大药厂	用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
UA72611C2 (uk) *	2000-05-17	2005-03-15	Орто-Макнейл Фармацевтикал, Інк.	Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
UA74826C2 (en)	2000-05-17	2006-02-15	Ortho Mcneil Pharm Inc	?-carboline derivatives as phosphodiesterase inhibitors
JP2004501124A (ja)	2000-06-07	2004-01-15	リリー　アイコス　リミテッド　ライアビリティ　カンパニー	化合物
US20030153575A1 (en) *	2000-06-08	2003-08-14	Orme Mark W.	Tetracyclic diketopiperazine compounds as pdev inhibitors
US6911542B2 (en) *	2000-06-23	2005-06-28	Lilly Icos Llc.	Pyrazino[1′,2′:1,6]pyrido[3,4b]indole derivatives
MXPA02012659A (es) *	2000-06-26	2003-09-22	Lilly Icos Llc	Derivados de pirazindiona condensados.
WO2002010166A1 (en) *	2000-08-02	2002-02-07	Lilly Icos Llc	Fused heterocyclic derivatives as phosphodiesterase inhibitors
CN1264574C (zh) *	2000-09-06	2006-07-19	田边制药株式会社	口服制剂
US6821978B2 (en)	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
US6962918B2 (en) *	2000-10-02	2005-11-08	Lilly Icos Llc.	Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
MXPA03004023A (es)	2000-11-08	2004-02-12	Lilly Icos Llc	Compuestos quimicos.
NZ527585A (en) *	2001-02-15	2005-04-29	Tanabe Seiyaku Co	Tablets quickly disintegrated in oral cavity
DE10118305A1 (de) *	2001-04-12	2002-10-17	Bayer Ag	Zusammensetzungen zur nasalen Applikation
WO2002083631A1 (en)	2001-04-13	2002-10-24	Sepracor Inc.	Methods of preparing didesmethylsibutramine and other sibutramine derivatives
ES2307758T3 (es) *	2001-06-05	2008-12-01	Lilly Icos Llc	Derivados de pirazino (1',2':1,6)pirido(3,4-b)indol 1,4-diona.
ATE395349T1 (de) *	2001-08-28	2008-05-15	Schering Corp	Polycyclische guanin phosphodiesterase inhibitoren
US20030087963A1 (en)	2001-09-13	2003-05-08	Senanayake Chris H.	Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
CA2465893A1 (en) *	2001-11-09	2003-05-22	Schering Corporation	Polycyclic guanine derivative phosphodiesterase v inhibitors
ES2289159T3 (es)	2001-11-14	2008-02-01	Ortho-Mcneil Pharmaceutical Corporation	Derivados tetraciclicos sustituidos de pirroloquinolona utilizados como inhibidores de fosfodiesterasa.
DE60235198D1 (de) *	2001-12-20	2010-03-11	Merck Serono Sa Coinsins	Pyrrolidin-derivatie als prostaglandin-modulatoren
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en)	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en)	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
DE10232113A1 (de)	2002-07-16	2004-01-29	Bayer Ag	Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
AU2003257289A1 (en)	2002-07-26	2004-02-16	Kenneth W. Adams	Pharmaceutical compositions for penis enlargement
WO2005068464A2 (en) *	2003-12-15	2005-07-28	Cadila Healthcare Limited	Process for preparing tadalafil and its intermediates
EP1750766B1 (en)	2004-05-11	2013-07-03	Emotional Brain B.V.	Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US20060235005A1 (en) *	2005-04-14	2006-10-19	Oak Labs, Corp.	Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
US8506934B2 (en)	2005-04-29	2013-08-13	Robert I. Henkin	Methods for detection of biological substances
US20070010525A1 (en) *	2005-06-27	2007-01-11	Meyer Jackson	Method and compositions for modulating neuropeptide hormone secretion
AU2006275702A1 (en)	2005-07-29	2007-02-08	Concert Pharmaceuticals Inc.	Novel pharmaceutical compounds
EP2258358A3 (en)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
JP2009507925A (ja) *	2005-09-13	2009-02-26	エランファーマインターナショナルリミテッド	ナノ粒子タダラフィル製剤
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
JP2009514969A (ja)	2005-11-09	2009-04-09	コンビナトアールエックスインコーポレーティッド	医学的状態を治療するための方法、組成物、およびキット
EP1790343A1 (en)	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US20080027072A1 (en) *	2006-04-20	2008-01-31	Ampla Pharmaceuticals, Inc.	Potentiation of MC4 receptor activity
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
KR101140110B1 (ko) *	2006-07-07	2012-06-04	테바 파마슈티컬 인더스트리즈 리미티드	타달라필 및 하나 이상의 담체를 포함하는 고체 조성물
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP1925307A1 (en)	2006-11-03	2008-05-28	Emotional Brain B.V.	Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008095136A2 (en)	2007-01-31	2008-08-07	Henkin Robert I	Methods for detection of biological substances
CN101674728A (zh)	2007-02-12	2010-03-17	Dmi生物科学公司	降低曲马多的副作用
CA2677690C (en)	2007-02-12	2012-05-15	James V. Winkler	Treatment of comorbid premature ejaculation and erectile dysfunction
US20090098211A1 (en) *	2007-04-25	2009-04-16	Ilan Zalit	Solid dosage forms
DE102007028869A1 (de)	2007-06-22	2008-12-24	Ratiopharm Gmbh	Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
WO2009091777A1 (en) *	2008-01-15	2009-07-23	Forest Laboratories Holdings Limited	Nebivolol in the treatment of sexual dysfunction
MX2010011963A (es)	2008-05-02	2010-12-06	Gilead Sciences Inc	Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
US8580801B2 (en)	2008-07-23	2013-11-12	Robert I. Henkin	Phosphodiesterase inhibitor treatment
AR073522A1 (es)	2008-09-30	2010-11-10	Biolab Sanus Farmaceutica Ltda	Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US8586587B2 (en)	2009-02-26	2013-11-19	Thar Pharmaceuticals, Inc.	Crystalline molecular complex of tadalafil and methylparaben
DE102009033396A1 (de)	2009-07-16	2011-01-20	Ratiopharm Gmbh	Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US20110136815A1 (en)	2009-12-08	2011-06-09	Horst Zerbe	Solid oral film dosage forms and methods for making same
US10610528B2 (en) *	2009-12-08	2020-04-07	Intelgenx Corp.	Solid oral film dosage forms and methods for making same
UY33535A (es) *	2010-08-13	2011-12-01	Biolab Sanus Farmaceutuca Limitada	Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona
AU2012323890A1 (en)	2011-10-14	2014-05-29	Array Biopharma Inc.	Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use
MX357741B (es) *	2012-07-06	2018-07-23	Laboratorios Senosiain S A De C V Star	Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
WO2014055801A1 (en)	2012-10-05	2014-04-10	Henkin Robert I	Phosphodiesterase inhibitors for treating taste and smell disorders
EP3054951A4 (en) *	2013-10-07	2017-05-10	Millennium Pharmaceuticals, Inc.	Inhibitor of breast cancer resistance protein (bcrp)
US10598672B2 (en)	2014-02-18	2020-03-24	Cyrano Therapeutics, Inc.	Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
MX2016014384A (es)	2014-06-23	2017-01-20	Celgene Corp	Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
CN104086546B (zh) *	2014-07-14	2016-08-17	福建广生堂药业股份有限公司	他达拉非的药用酸盐及其制备方法
MX2019006938A (es)	2016-12-14	2019-09-06	Respira Therapeutics Inc	Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
SI3510997T1 (sl)	2018-01-10	2020-12-31	Gap S.A.	Mehke želatinaste kapsule, ki vsebujejo suspenzijo Tadalafila
CN112955967A (zh) *	2018-06-14	2021-06-11	阿斯利康(英国)有限公司	用cgmp特异性磷酸二酯酶5抑制剂医药组合物治疗勃起功能障碍的方法
JP7606530B2 (ja)	2020-03-24	2024-12-25	シラノセラピューティクス，インコーポレイテッド	コロナウイルス感染症による化学感覚機能障害の治療
WO2021245192A1 (en)	2020-06-04	2021-12-09	Topadur Pharma Ag	Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3644384A (en) *	1969-06-09	1972-02-22	Sterling Drug Inc	Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) *	1971-03-11	1973-02-20	Sterling Drug Inc	1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) *	1973-03-30	1975-11-04	Council Scient Ind Res	2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) *	1973-10-19	1976-10-27	Council Scient Ind Res	Tetracyclic compounds
US4188390A (en) *	1977-11-05	1980-02-12	Pfizer Inc.	Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GR79603B (cs) *	1982-07-24	1984-10-31	Pfizer
IT1217190B (it) *	1988-04-22	1990-03-14	Recordati Chem Pharm	Composti utili per il trattamento e diagnosi di disfunzioni frettili
EP0357122A3 (en) *	1988-08-29	1991-10-23	Duphar International Research B.V	Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (de) *	1988-09-03	1990-03-15	Hoechst Ag	Piperazindione mit psychotroper wirkung
KR0167346B1 (ko) *	1989-06-09	1999-01-15	로버트 에이. 아미테이지	중추신경계 활성을 갖는 헤테로사이클릭 아민
FR2649613B1 (fr) *	1989-07-11	1991-09-27	Virag Ronald	Medicament vaso-actif
JPH0344324A (ja) *	1989-07-13	1991-02-26	Kazuoki Tsuchiya	性機能賦活剤
US5270323A (en) *	1990-05-31	1993-12-14	Pfizer Inc.	Method of treating impotence
EP0459666B1 (en) *	1990-05-31	1994-11-09	Pfizer Inc.	Medicaments against impotence
GB9012469D0 (en) *	1990-06-05	1990-07-25	Glaxo Group Ltd	Medicaments
GB9013750D0 (en) *	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
GB9114760D0 (en) *	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
DE4218979A1 (de) *	1992-06-10	1993-12-16	Cassella Ag	Pyrimidofuroxane
GB9311920D0 (en) *	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
GB9401090D0 (en) *	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds

1995
- 1995-07-14 GB GBGB9514464.8A patent/GB9514464D0/en active Pending
1996
- 1996-07-11 EP EP96923985A patent/EP0839040B1/en not_active Expired - Lifetime
- 1996-07-11 ES ES96923985T patent/ES2267111T3/es not_active Expired - Lifetime
- 1996-07-11 RU RU98102398/14A patent/RU2181288C2/ru active
- 1996-07-11 PL PL96324495A patent/PL185737B1/pl unknown
- 1996-07-11 AU AU64191/96A patent/AU704955B2/en not_active Expired
- 1996-07-11 PT PT96923985T patent/PT839040E/pt unknown
- 1996-07-11 AT AT96923985T patent/ATE327756T1/de active
- 1996-07-11 WO PCT/EP1996/003024 patent/WO1997003675A1/en not_active Ceased
- 1996-07-11 BR BR9609758A patent/BR9609758A/pt unknown
- 1996-07-11 DK DK96923985T patent/DK0839040T3/da active
- 1996-07-11 JP JP50624897A patent/JP4169365B2/ja not_active Expired - Lifetime
- 1996-07-11 CN CNB021557918A patent/CN1311828C/zh not_active Expired - Lifetime
- 1996-07-11 CZ CZ199833A patent/CZ289686B6/cs not_active IP Right Cessation
- 1996-07-11 DE DE69636193T patent/DE69636193T2/de not_active Expired - Lifetime
- 1996-07-11 SK SK39-98A patent/SK284141B6/sk not_active IP Right Cessation
- 1996-07-11 MX MXPA02009987A patent/MXPA02009987A/es active IP Right Grant
- 1996-07-11 PL PL96357665A patent/PL185999B1/pl unknown
- 1996-07-11 CN CN96196723A patent/CN1112928C/zh not_active Expired - Lifetime
- 1996-07-11 HU HU9900065A patent/HU228369B1/hu unknown
- 1996-07-11 SI SI9630740T patent/SI0839040T1/sl unknown
- 1996-07-11 IL IL12287096A patent/IL122870A/en not_active IP Right Cessation
- 1996-07-11 CA CA002226784A patent/CA2226784C/en not_active Expired - Lifetime
- 1996-07-11 US US08/981,989 patent/US6140329A/en not_active Expired - Lifetime
- 1996-07-11 SK SK1259-2003A patent/SK284494B6/sk not_active IP Right Cessation
1998
- 1998-01-13 MX MX9800414A patent/MX9800414A/es unknown
- 1998-01-13 NO NO19980153A patent/NO314685B1/no not_active IP Right Cessation
2000
- 2000-05-18 US US09/573,905 patent/US6608065B1/en not_active Expired - Lifetime
2006
- 2006-09-04 CY CY0600024A patent/CY2563B1/xx unknown
- 2006-11-02 CY CY200600007C patent/CY2006007I2/el unknown

Also Published As

Publication number	Publication date
MXPA02009987A (es)	2003-02-28
AU6419196A (en)	1997-02-18
AU704955B2 (en)	1999-05-13
MX9800414A (es)	1998-06-30
SK284494B6 (sk)	2005-05-05
HUP9900065A3 (en)	1999-11-29
BR9609758A (pt)	1999-01-26
CZ289686B6 (cs)	2002-03-13
GB9514464D0 (en)	1995-09-13
PL324495A1 (en)	1998-05-25
RU2181288C2 (ru)	2002-04-20
CA2226784C (en)	2003-07-08
JPH11509221A (ja)	1999-08-17
ES2267111T3 (es)	2007-03-01
ATE327756T1 (de)	2006-06-15
IL122870A0 (en)	1998-08-16
DK0839040T3 (da)	2006-09-25
CY2563B1 (en)	2008-07-02
WO1997003675A1 (en)	1997-02-06
IL122870A (en)	2002-03-10
HK1005363A1 (en)	1999-01-08
CN1513452A (zh)	2004-07-21
DE69636193T2 (de)	2007-04-26
CA2226784A1 (en)	1997-02-06
NO980153L (no)	1998-03-10
HU228369B1 (en)	2013-03-28
CN1311828C (zh)	2007-04-25
US6140329A (en)	2000-10-31
EP0839040B1 (en)	2006-05-31
EP0839040A1 (en)	1998-05-06
SK284141B6 (sk)	2004-10-05
PL185737B1 (pl)	2003-07-31
DE69636193D1 (de)	2006-07-06
NO980153D0 (no)	1998-01-13
CY2006007I1 (el)	2009-11-04
JP4169365B2 (ja)	2008-10-22
US6608065B1 (en)	2003-08-19
CN1112928C (zh)	2003-07-02
PL185999B1 (pl)	2003-09-30
SI0839040T1 (sl)	2006-10-31
HUP9900065A2 (hu)	1999-05-28
PT839040E (pt)	2006-09-29
CN1195290A (zh)	1998-10-07
CZ3398A3 (cs)	1998-05-13
SK3998A3 (en)	1998-07-08
CY2006007I2 (el)	2009-11-04

Legal Events

Date	Code	Title	Description
2016-07-18	MK1K	Patent expired

Publication	Publication Date	Title
NO314685B1 (no)	2003-05-05	Anvendelse av cGMP-fosfodiesteraseinhibitorer for fremstilling av et medikament for behandling av erektil dysfunksjon eller seksuelldysfunksjon forbundetmed klitorisforstyrrelser hos en kvinne
US6143757A (en)	2000-11-07	Chemical compounds
US5981527A (en)	1999-11-09	Cyclic GMP-specific phosphodiesterase inhibitors
US6143746A (en)	2000-11-07	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
RU2142463C1 (ru)	1999-12-10	Тетрациклические производные, способ их получения (варианты), содержащий их фармацевтический состав, и их использование в терапии
EP1129093A1 (en)	2001-09-05	Pyrazolopyrimidinone derivatives for the treatment of impotence
US6686349B2 (en)	2004-02-03	Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
WO2000002881A2 (fr)	2000-01-20	Utilisation de derives de la cysteine pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimerique
KR20030005176A (ko)	2003-01-17	4-피리딜- 및 2,4-피리미디닐-치환된 피롤 유도체 및 그의제약학에서의 용도
HK1005363B (en)	2006-12-01	Use of cgmp - phosphodiesterase inhibitors to treat impotence
CZ289832B6 (cs)	2002-04-17	Léčivo pro léčení nebo prevenci samičí sexuální dysfunkce
HK1158519A (en)	2012-07-20	Tetracyclic cyclic gmp-specific phosphodiesterase inhibitors for the treatment of benign prostatic hypertrophy
HK1128423A (en)	2009-10-30	(6r,12ar)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy